Real IntelligenceReviewIndependent Clinical Evaluation
Back to Atlas

Cardiac signal analysis

Kardia 12L

AliveCor

A portable 12-lead ECG system that uses cleared AI to provide multiple cardiac determinations.

Designed for

Healthcare professional

Care setting

Point of care

Specialty

Cardiology, Primary care, Emergency medicine

Public evidence assessedReviewed August 31, 2026

Our assessment

Bottom line

Kardia 12L has credible technical and regulatory support for simplified 12-lead acquisition, with early clinical evidence for workflow efficiency. Public evidence is less complete for current-version accuracy across every marketed AI determination and for patient-level impact.

Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.

What the evidence supports

Reviewed sources establish a marketed, FDA-cleared AI-powered 12-lead ECG system for professional use.

What remains uncertain

Independent current-version performance for each determination, subgroup behavior, and clinical pathway impact remains outside this profile.

How it was studied

Kardia 12L has regulatory and technical evidence comparing its reduced-lead acquisition and AI determinations with standard 12-lead ECG references. A clinical workflow study reported acquisition time and whether recordings were sufficient for clinical use.

Product facts

Intended use
Capture a clinical 12-lead ECG and provide supported AI cardiac determinations for professional review.
Represented version
Kardia 12L ECG System with KAI 12L AI technology
Regulatory context
AliveCor reports FDA clearance for the Kardia 12L ECG System and KAI 12L technology. Exact labeling should be confirmed before use.

Sources reviewed

3 public sources represented in this evidence profile.

Clinical efficiency study of Kardia 12LPrimary evidenceKardia 12L clearance and launchOfficial productAliveCor health system solutionsOfficial documentation
For clinical and investment reviewEvidence context and questions for deeper review

Evidence source base

Developer-supported regulatory and conference evidence plus emerging published workflow studies. Determination-specific validation should be separated.

Important limitation

Technical equivalence and acquisition efficiency do not establish current-version accuracy for every one of the marketed determinations or patient-level outcome benefit.

Questions to ask

  1. 01Which determinations are enabled in the deployed configuration?
  2. 02How are low-quality or inconclusive ECGs handled?
  3. 03What review is required before acting on a result?
Return to AtlasHow RIR evaluates evidence